

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3506.1000-002	APPLICATION NO. 10/757,364
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b> OCT 04 2006 (Use several sheets if necessary)		FIRST NAMED INVENTOR Steven B. Landau	FILING DATE January 13, 2004
		EXAMINER Yong Soo Chong	CONFIRMATION NO. 3343
			GROUP 1617

U.S. PATENT DOCUMENTS				
EXAM- INER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
YC	AD6	US 2005/0239792	10-27-2005	Cavalla <i>et al.</i>
	AE6	US 6,008,227	12-28-1999	Davies <i>et al.</i>

FOREIGN PATENT DOCUMENTS				
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AQ3	EP 0 150 469	06-15-1988	Mitsubishi
	AL4	CA 2431074	6-27-2002	Merck Patent GMBH
	AM4	DE 100 63 223	6-20-2002	Merck Patent GMBH

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AWS	Crowell, M. D., "The Role of Serotonin in the Pathophysiology of Irritable Bowel Syndrome," <i>Am. J. Man. Care</i> , 7: S252-S260 (2001).

EXAMINER <i>Yong Chong</i>	DATE CONSIDERED 7/16/07
-------------------------------	----------------------------

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 3506.1000-002	APPLICATION NO. 10/757,364
O I P F INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION May 26, 2006 May 24, 2006 Use several sheets if necessary)			FIRST NAMED INVENTOR Steven B. Landau	FILING DATE January 13, 2004
			EXAMINER Yong Soo Chong	CONFIRMATION NO. 3343
				GROUP 1617

U.S. PATENT DOCUMENTS				
EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
YC	AF5	6,475,078 B2	11-05-2002	Jerussi <i>et al.</i>
	AG5	2004/0254168 A1	12-16-2004	Landau
	AH5	2004/0254169 A1	12-16-2004	Landau
	AJ5	2004/0254170 A1	12-16-2004	Landau
	AJ5	2004/0259862 A1	12-23-2004	Landau
	AK5	2005/0032780 A1	02-10-2005	Landau
	AA6	2004/0254171 A1	12-16-2004	Landau <i>et al.</i>
	AB6	2004/0254172 A1	12-16-2004	Landau <i>et al.</i>
	AC6	2004/0147510 A1	07-29-2004	Landau

FOREIGN PATENT DOCUMENTS				
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AP3	WO 2004/062624 A3	07-29-2004	Dynogen Pharmaceuticals, Inc.

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AS5	Steadman, C.J., <i>et al.</i> , "Selective 5-Hydroxytryptamine Type 3 Receptor Antagonism With Ondansetron as Treatment for Diarrhea-Predominant Irritable Bowel Syndrome: A Pilot Study," <i>Mayo Clinic Proc.</i> , 67(8): 732-738 (1992).
	AT5	"Dynogen Pharmaceuticals, Inc. Enters Into Agreement With Mitsubishi Pharma For Irritable Bowel Syndrome Compound," Dynogen Pharmaceuticals, Inc. Press Release, pp. 1-2 [online], (December 22, 2003). Retrieved from the Internet <URL: <a href="http://www.dynogen.com">www.dynogen.com</a> >.
	AUS	Database IMSDRUGNEWS, R&D Focus Drug News, "DDP 225 Dynogen, Mitsubishi Pharma Licensing Agreement," [online], January 12, 2004. Retrieved from: STN Database, Accession No. 2004:188.
	AV5	Database CIN 2004-01-05, "Life Sciences in Brief," [online], January 5, 2004 (retrieved online January 31, 2006). Retrieved from: STN Database, Accession No. 33(3):1518T..

EXAMINER 	DATE CONSIDERED 7/16/07
---	----------------------------

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3506.1000-002	APPLICATION NO. 10/757,364
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		FIRST NAMED INVENTOR Steven B. Landau
April 8, 2005 (Use several sheets if necessary)	APR 15 2005 U.S. PATENT & TRADEMARK OFFICE RECEIVED	FILING DATE January 13, 2004
EXAMINER	CONFIRMATION NO. 3343	GROUP 1653


## U.S. PATENT DOCUMENTS

EXAMINER 	DATE CONSIDERED 7/16/07
---	----------------------------

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3506.1000-002	APPLICATION NO. 10/757,364
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION		FIRST NAMED INVENTOR Steven B. Landau
April 8, 2005  (Use several sheets if necessary)	APR 15 2005 EXAMINER	FILING DATE January 13, 2004
		CONFIRMATION NO. 3343
		GROUP 1653

EXAMINER 	DATE CONSIDERED 7/16/07
---	----------------------------

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 3506.1000-002	APPLICATION NO. 10/757,364
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION		FIRST NAMED INVENTOR Steven B. Landau	FILING DATE January 13, 2004
December 6, 2004 (Use several sheets if necessary)		EXAMINER	CONFIRMATION NO. 3343
			GROUP 1653



FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
YL	ALJ	WO 2004/058353 A3	07-15-2004	Amedis Pharmaceuticals, LTD.	

EXAMINER 	DATE CONSIDERED 7/16/07
--------------	----------------------------

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3506.1000-002	APPLICATION NO. 10/757,364
<b>SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>	FIRST NAMED INVENTOR Steven B. Landau	FILING DATE January 13, 2004
September 27, 2004  (Use several sheets if necessary)	EXAMINER	CONFIRMATION NO. 3343
		GROUP


## U.S. PATENT DOCUMENTS

**EXAMINER**

**DATE CONSIDERED**

7/6/07

PTO-1449 REPRODUCED



March 19, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO.  
3506.1000-002APPLICATION NO.  
10/757,364FIRST NAMED INVENTOR  
Steven B. LandauFILING DATE  
January 13, 2004EXAMINER  
UnknownCONFIRMATION NO.  
UnknownGROUP  
Unknown

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
YL	AB5	2003/0158221 A1	08-21-2003	Zhang <i>et al.</i>

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
YL	AQ2	WO 03/061657 A1	07-31-2003	Aryx Therapeutics	

EXAMINER

DATE CONSIDERED

7/16/07

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 3506.1000-002	APPLICATION NO. 10/757,364	
O I P E INFORMATION DISCLOSURE CITATION IN AN APPLICATION			FIRST NAMED INVENTOR Steven B. Landau	FILING DATE January 13, 2004	
February 11, 2004 (Use several sheets if necessary)			EXAMINER Unknown	CONFIRMATION NO. Unknown	GROUP Unknown

U.S. PATENT DOCUMENTS					
EXAM- INER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	
YL	AA	4,695,568	09-22-1987	Ninomiya <i>et al.</i>	
	AB	4,939,136	07-03-1990	Haeck <i>et al.</i>	
	AC	5,225,407	07-06-1993	Oakley <i>et al.</i>	
	AD	5,352,685	10-04-1994	Maruyama <i>et al.</i>	
	AE	5,434,174	07-18-1995	Gidda <i>et al.</i>	
	AF	5,438,068	08-01-1995	Eeckhout <i>et al.</i>	
	AG	5,470,868	11-28-1995	Young	
	AH	5,576,317	11-19-1996	Gonsalves	
	AI	5,663,343	09-02-1997	van der Meij <i>et al.</i>	
	AJ	5,945,415	08-31-1999	Kato <i>et al.</i>	
	AK	5,962,494	10-05-1999	Young	
	AA2	5,977,175	11-02-1999	Lin	
	AB2	5,985,866	11-16-1999	Müller <i>et al.</i>	
	AC2	5,990,159	11-23-1999	Meulemans <i>et al.</i>	
	AD2	6,054,461	04-25-2000	Fairbanks <i>et al.</i>	
	AE2	6,117,879	09-12-2000	Fairbanks <i>et al.</i>	
	AF2	6,156,771	12-05-2000	Rubin <i>et al.</i>	
	AG2	6,235,745 B1	05-22-2001	Megens	
	AH2	6,284,770 B1	09-04-2001	Mangel <i>et al.</i>	
	AI2	6,300,336 B1	10-09-2001	Eeckhout <i>et al.</i>	
	AJ2	6,355,647 B1	03-12-2002	Steiner <i>et al.</i>	
	AK2	6,384,042 B2	05-07-2002	Färber <i>et al.</i>	
	AA3	6,429,209 B2	08-06-2002	Mangel <i>et al.</i>	
	AB3	6,440,453 B1	08-27-2002	Fischer <i>et. al.</i>	
	AC3	6,441,038 B1	08-27-2002	Loder <i>et al.</i>	
	AD3	6,458,795 B1	10-01-2002	Bergeron, Jr.	

EXAMINER <i>Yang Chang</i>	DATE CONSIDERED <i>7/16/07</i>
-------------------------------	-----------------------------------

<p>PTO-1449 REPRODUCED</p> <p>O I P INFORMATION DISCLOSURE CITATION IN AN APPLICATION</p> <p>February 11, 2004</p> <p>(use several sheets if necessary)</p>	ATTORNEY DOCKET NO.	APPLICATION NO.
	3506.1000-002	10/757,364
	FIRST NAMED INVENTOR	FILING DATE
	Steven B. Landau	January 13, 2004
EXAMINER	CONFIRMATION NO.	GROUP
Unknown	Unknown	Unknown

## **U.S. PATENT DOCUMENTS**

EXAMINER 	DATE CONSIDERED 7/16/07
---	----------------------------

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3506.1000-002	APPLICATION NO. 10/757,364
O I P INFORMATION DISCLOSURE CITATION IN AN APPLICATION February 11, 2004 <i>Please use several sheets if necessary</i>	FIRST NAMED INVENTOR Steven B. Landau	FILING DATE January 13, 2004
	EXAMINER Unknown	CONFIRMATION NO. Unknown
		GROUP Unknown

## FOREIGN PATENT DOCUMENTS

EXAMINER 	DATE CONSIDERED <u>7/16/67</u>
--	--------------------------------

PTO-1449 REPRODUCED




INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION  
February 11, 2004  
(use several sheets if necessary)


ATTORNEY DOCKET NO. 3506.1000-002	APPLICATION NO. 10/757,364	
FIRST NAMED INVENTOR Steven B. Landau	FILING DATE January 13, 2004	
EXAMINER Unknown	CONFIRMATION NO. Unknown	GROUP Unknown

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

YL	AR	Depoortere, I., <i>et al.</i> , "Dose-Dependent Effects of Recombinant Human Interleukin-11 on Contractile Properties in Rabbit 2,4,6-Trinitrobenzene Sulfonic Acid Colitis <sup>1</sup> ," <i>J. Pharmacol. Exp. Ther.</i> , 294(3): 983-990 (2000).
	AS	Million, M., <i>et al.</i> , "Susceptibility of Lewis and Fischer Rats to Stress-induced Worsening of TNB-colitis: Protective Role of Brain CRF," <i>Amer. Phys. Soc.</i> , 276 (4 Pt 1): G1027-G1036 (1999).
	AT	Owens, M. J., <i>et al.</i> , "Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and their Metabolites <sup>1</sup> ," <i>J. Pharmacol. Exp. Ther.</i> , 283(3): 1305-1322 (1997).
	AU	Kozlowski, C.M., <i>et al.</i> , "The 5-HT <sub>3</sub> Receptor Antagonist Alosetron Inhibits the Colorectal Distention Induced Depressor Response and Spinal c-fos Expression in the Anaesthetised Rat," <i>Gut</i> , 46: 474-480 (2000).
	AV	Ito, C., <i>et al.</i> , "Effect of GK-128 [2-[(2-Methylimidazol-1-yl)methyl]- benzo[f]thiochromen-1-one Monohydrochloride Hemihydrate], a Selective 5-Hydroxytryptamine, Receptor Antagonist, on Colonic Function in Rats," <i>J. Pharmacol. Exp. Ther.</i> , 280(1): 67-72 (1997).
	AW	Eguchi, J., <i>et al.</i> , "Pharmacological Profile of the Novel Antidepressant 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno-[2,3-d]pyrimidine Monohydrate Hydrochloride," <i>Arzneimittelforschung</i> , 47(12): 1337-1347 (1997).
	AX	Venkova, K., <i>et al.</i> , "Peripheral Activity of a New NK <sub>1</sub> Receptor Antagonist TAK-637 in the Gastrointestinal Tract," <i>J. Pharmacol. Exp. Ther.</i> , 300(3): 1046-1052 (2002).
	AY	Yuan, S.Y., <i>et al.</i> , "Investigation of the Role of 5-HT <sub>3</sub> and 5-HT <sub>4</sub> Receptors in Ascending and Descending Reflexes to the Circular Muscle of Guinea-pig Small Intestine," <i>Br. J. Pharmacol.</i> , 112(4): 1095-1100 (1994).
	AZ	Jin, J.G., <i>et al.</i> , "Propulsion in Guinea Pig Colon Induced by 5-Hydroxytryptamine (HT) Via 5-HT <sub>4</sub> and 5-HT <sub>3</sub> Receptors <sup>1</sup> ," <i>J. Pharmacol. Exp. Ther.</i> , 288(1): 93-97 (1999).
	AR2	Greenbaum, D.S., <i>et al.</i> , "Effects of Desipramine on Irritable Bowel Syndrome Compared with Atropine and Placebo," <i>Digestive Diseases and Sciences</i> , 32(3): 257-266 (1987).
	AS2	Center for Drug Evaluation and Research Application Number: 020623; Pharmacology Reviews; July 5, 1996.

EXAMINER 	DATE CONSIDERED 7/16/07
---	----------------------------

PTO-1449 REPRODUCED


ATTORNEY DOCKET NO.  
3506.1000-002APPLICATION NO.  
10/757,364FIRST NAMED INVENTOR  
Steven B. LandauFILING DATE  
January 13, 2004EXAMINER  
UnknownCONFIRMATION NO.  
UnknownGROUP  
Unknown

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

4C	AT2	Eguchi, J., et al., "The Anxiolytic-Like Effect of MCI-225, A Selective NA Reuptake Inhibitor with 5-HT <sub>3</sub> Receptor Antagonism," <i>Pharm. Biochem. and Behavior</i> , 68:677-683 (2001).
	AU2	Schmulson, M.J., "Brain-Gut Interaction in Irritable Bowel Syndrome: New Findings of a Multicomponent Disease Model," <i>IMAJ</i> , 3:104-110 (2001).
	AV2	Camilleri, M., "Serotonergic Modulation of Visceral Sensation: Lower Gut," <i>Gut</i> 51(1):81-86 (2002).
	AW2	Camilleri, M., "Serotonergic Drugs: Emerging Therapies for Irritable Bowel Syndrome," In <i>Irritable Bowel Syndrome a Clinician's Guide</i> , M. Camilleri and R. C. Spiller, eds., Chapt. 19; pp 1-10 (2002).
	AX2	Wood, J.D., et al. "Fundamentals of Neurogastroenterology," <i>Gut</i> 45(2):II6-II16 (1999).
	AY2	Burns, M.J., "The Pharmacology and Toxicology of Reboxetine," <i>Int. J. Med. Toxicol.</i> 3(4):26 1-8 (2000).
	AZ2	Thompson, W.G., et al., "Functional Bowel Disorders and Functional Abdominal Pain," <i>Gut</i> 45:II43-II47 (1999).
	AR3	Sheikh, M. Y. and Wright, R.A., "Irritable Bowel Syndrome: Current Concepts and Future Prospects," <i>Hospital Physician</i> , pp. 31-38 (March 1999).
	AS3	Schmulson, M.J., "Brain-Gut Interaction in Irritable Bowel Syndrome: New Findings of a Multicomponent Disease Model," <i>IMAJ</i> 3:104-110 (2001).
	AT3	Gebhart, G.F., "Pathobiology of Visceral Pain: Molecular Mechanisms and Therapeutic Implications IV. Visceral Afferent Contributions to the Pathobiology of Visceral Pain," <i>Am. J. Physiol. Gastrointest. Liver Physiol.</i> 278:G834-G838 (2000).
	AU3	Mertz, H.R., "Irritable Bowel Syndrome," <i>N. Engl. J. Med.</i> 349:2136-2146 (2003).
	AV3	Bymaster, F.P., et al. "Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters <i>In Vitro</i> and <i>In Vivo</i> , Human Serotonin Receptor Subtypes, and Other Neuronal Receptors," <i>Neuropsychopharmacology</i> , 25(6):871-880 (2001).
	AW3	Béique, J.C., et al., "Affinities of Venlafaxine and Various Reuptake Inhibitors for the Serotonin and Norepinephrine Transporters," <i>Eur. J. Pharmacol.</i> , 349(1):129-132 (1998).

EXAMINER	DATE CONSIDERED
----------	-----------------

PTO-1449 REPRODUCED



February 11, 2004

(use several sheets if necessary)

ATTORNEY DOCKET NO.  
3506.1000-002APPLICATION NO.  
10/757,364FIRST NAMED INVENTOR  
Steven B. LandauFILING DATE  
January 13, 2004EXAMINER  
UnknownCONFIRMATION NO.  
UnknownGROUP  
Unknown

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

YL	AX3	Wong, E.H.F., <i>et al.</i> , "Reboxetine: A Pharmacologically Potent, Selective, and Specific Norepinephrine Reuptake Inhibitor," <i>Biol. Psychiatry</i> , 47(9): 818-829 (2000).
	AY3	Sach, J.A., <i>et al.</i> , "Irritable Bowel Syndrome," <i>Curr. Treat. Options. Gastroenterol.</i> , 5(4): 267-278 (2002).
	AZ3	Angel, I., <i>et al.</i> , "Litoxetine: A Selective 5-HT Uptake Inhibitor with Concomitant 5-HT <sub>3</sub> Receptor Antagonist and Antiemetic Properties," <i>Eur. J. Pharmacol.</i> , 232(2-3):139-145 (1993).
	AR4	Fairweather, D.B., <i>et al.</i> , "The Psychomotor and Cognitive Effects of Litoxetine in Young and Middle Aged Volunteers," <i>Br. J. Clin. Pharmacol.</i> , 40(2):119-125 (1995).
	AS4	Morteau, O., <i>et al.</i> , "Influence of 5-HT <sub>3</sub> Receptor Antagonists in Visceromotor and Nociceptive Responses to Rectal Distension Before and During Experimental Colitis In Rats," <i>Fundam. Clin. Pharmacol.</i> , 8(6):553-562 (1994).
	AT4	Goldberg, P.A., <i>et al.</i> , "Modification of Visceral Sensitivity and Pain in Irritable Bowel Syndrome by 5-HT <sub>3</sub> Antagonism (Ondansetron)," <i>Digestion</i> , 57(6):478-483 (1996).
	AU4	LOTRONEX - Tablets, <i>Product Information</i> , GlaxoSmithKline, Research Triangle Park, NC, pp. 1-13 (2002).
	AV4	"Irritable Bowel Syndrome at a Glance - Nosology, Epidemiology, and Pathophysiology (Monograph I), December 2002 [Retrieved on 2002-12-12]. Retrieved from the Internet <URL: <a href="http://fdhn.org/html/education/gi/ibs_nosology.htm">http://fdhn.org/html/education/gi/ibs_nosology.htm</a> >
	AW4	U.S. Provisional Application No. 60/364,531, filed 03-15-2002, entitled "Methods of Treating Visceral Pain Syndromes," by Rao <i>et al.</i> , priority document for WO 03/077897 A1 (Reference AQ2) and U.S. 2003/0203055 A1 (Reference AF4).
	AX4	GB 0304648.9, filed 02-28-2003, entitled "New Therapeutic Use of 4-(2-Fluorophenyl)-6-Methyl-2-(1-Piperziny1) Thieno[2,3-D] Pyrimidine," priority document for WO 2004/004734 A1 (Reference AL2).
	AY4	GB 0216027.3, filed July 10, 2002, entitled "New Therapeutic Use," priority document for WO 2004/004734 A1 (Reference AL2).
	AZ4	Drossman, D.A., <i>et al.</i> , "Irritable Bowel Syndrome: A Technical Review for Practice Guideline Development," <i>Gastroenterology</i> , 112: 2120-2137 (1997).

EXAMINER

DATE CONSIDERED